$BICX News
Last published 11mo ago
- 11mo agoBICXBioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11thGlobeNewswireANAHEIM, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB:BICX), based in Anaheim, CA, focused on improving the wellness of those struggling with alcohol, opioid, and other addictive disorders, today
- 11mo agoBICXDTCFFECHQFGNVR+4Life Sciences Virtual Investor Forum Agenda Announced for December 11thGlobeNewswireNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th.
- 11mo agoBICXDiamond Equity Research Releases Update Note on BioCorRx®, Inc. (OTCQB: BICX)GlobeNewswireNew York, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update report on BioCorRx®, Inc. (OTCQB:BICX). The
- 1y agoBICXDiamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX)GlobeNewswireNew York, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has initiated coverage of BioCorRx®, Inc. (OTCQB:BICX). The
- 1y agoALBTBICXHTOOVMARFusion Fuel Appoints Luisa Ingargiola to Board of DirectorsGlobeNewswireDUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (NASDAQ:HTOO) ("Fusion Fuel" or the "Company"), a leading provider of gas and hydrogen energy solutions, today announced the
- 2y agoBICXBioCorRx Reports Business Update for the Second Quarter of 2024GlobeNewswireANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business
- 2y agoALBTBICXLRHCLa Rosa Appoints Corporate Finance Executive Lourdes Felix to its Board of DirectorsGlobeNewswireCelebration, FL, May 21, 2024 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a holding company for five agent-centric, technology-integrated, cloud-based, multi-service real
- 2y agoBICXBioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and SchizophreniaGlobeNewswireANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer of innovative treatment programs for substance use and related disorders, today announced
- 2y agoBICXBioCorRx Reports Business Update for 2023GlobeNewswireANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today
- 2y agoBICXBioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUDGlobeNewswireANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance use and related disorders, announced
- 2y agoBICXBioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of DirectorsGlobeNewswireANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders,
- 2y agoBICXBioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as PresidentGlobeNewswireANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders,
- 2y agoBICXBioCorRx Reports Business Update for the Third Quarter of 2023GlobeNewswireANAHEIM, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today
- 3y agoBICXBioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use DisorderGlobeNewswireCompany Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis ANAHEIM, CA, Aug. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc.
- 3y agoBICXBioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use DisorderGlobeNewswireANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today
- 3y agoBICXBioCorRx Provides Business Update for 2022GlobeNewswireRevenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics ANAHEIM, CA, April 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a
- 3y agoBICXBioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator MeetingGlobeNewswireBICX104 was Well Tolerated with No Serious Adverse Events Reported and Achieved 84 Days of Therapeutic Naltrexone Plasma ConcentrationsBICX104 Subjects Experienced Better 84-Day Treatment Adherence Than
- 3y agoBICXBioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 DataGlobeNewswireANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance use and related disorders, announced
- 3y agoBICXBioCorRx to Present at Sequire Biotechnology Conference on February 2ndGlobeNewswirePresentation on Thursday, February 2, 2023 at 2:00 PM ET ANAHEIM, CA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative
- 3y agoBICXBioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of DirectorsGlobeNewswireANAHEIM, CA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance use and related disorders, today
- 3y agoBICXBioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use DisorderGlobeNewswireANAHEIM, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance use and related disorders, today
- 3y agoALBTBICXAvalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of DirectorsGlobeNewswireFREEHOLD, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory
- 3y agoBICXBioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United StatesGlobeNewswireANAHEIM, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today
- 3y agoBICXBioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.GlobeNewswireANAHEIM, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today
- 3y agoBICXBioCorRx Provides Business Update for the Third Quarter of 2022GlobeNewswireANAHEIM, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today
- 4y agoBICXBioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use DisorderGlobeNewswireANAHEIM, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today
- 4y agoBICXBioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireANAHEIM, CA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CE
- 4y agoBICXBioCorRx Provides Business Update for the Second Quarter of 2022GlobeNewswireANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for th
- 4y agoBICXBioCorRx to Participate in the Benzinga All Access Event on July 15thGlobeNewswireANAHEIM, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, Pre
- 4y agoBICXBioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use DisorderGlobeNewswireANAHEIM, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the first subject
- 4y agoBICXBioCorRx Featured on LiveNOW from FOXGlobeNewswireANAHEIM, CA, June 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Tom Welch, Executi
- 4y agoBICXBioCorRx to Present at the LD Micro Invitational XII on June 7thGlobeNewswireANAHEIM, CA, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chi
- 4y agoBICXBioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse SettingGlobeNewswireCollaboration to create a synergistic treatment offering, combining BioCorRx's MAT treatment program and 2B3D virtual reality technology Plans toward expanding the offering to other at-risk groups upon evaluating results of pilot with veterans ANAH
- 4y agoBICXBioCorRx Business Update for the First Quarter of 2022GlobeNewswireANAHEIM, CA, May 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for t
- 4y agoBICXBioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use DisorderGlobeNewswireANAHEIM, CA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has begun the
- 4y agoBICXBioCorRx to Present at the Planet MicroCap Showcase 2022 in Las Vegas on May 4thACCESS NewswireANAHEIM, CA / ACCESSWIRE / April 26, 2022 / BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs fr substance abuse and related disorders, today announced that it will present at the Planet MicroCap Showca
- 4y agoBICXBioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use DisorderGlobeNewswireANAHEIM, CA, April 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has been awar
- 4y agoBICXBioCorRx Provides 2021 Year-End Business UpdateGlobeNewswireANAHEIM, CA, April 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a year-end business up
- 4y agoBICXBioCorRx to Participate in Two Upcoming ConferencesGlobeNewswireANAHEIM, CA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will
- 4y agoBICXBioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use DisorderGlobeNewswireANAHEIM, CA, March 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced it has received Indep
- 4y agoBICXBioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104GlobeNewswireANAHEIM, CA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, is pleased to announce that it has comp
- 4y agoBICXBioCorRx to Present at the H.C. Wainwright BioConnect 2022 ConferenceGlobeNewswireANAHEIM, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Fel
- 4y agoBICXBioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory BoardGlobeNewswireANAHEIM, CA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the appointment of Dr. J
- 4y agoBICXBioCorRx to Participate in the Benzinga All Access Event on December 2ndGlobeNewswireANAHEIM, CA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CE
- 4y agoBICXBioCorRx Acquires Intellectual Property for Drug DeliveryGlobeNewswirePatent Application Covers Solid Implant Formulation for Drug Delivery ANAHEIM, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for subst
- 4y agoBICXBioCorRx Provides Business Update for the Third Quarter of 2021GlobeNewswireANAHEIM, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for
- 5y agoAAZZFABIOACOGFACST+81Investor Summit Group Provides Update on Upcoming Q4 Virtual SummitGlobeNewswireNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the upcoming Q4 Virtual Summit on November 16-17. The e
- 5y agoBICXBioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone ImplantGlobeNewswireANAHEIM, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent appl
- 5y agoBICXBioCorRx to Present at LD Micro Main Event on Tuesday, October 12thGlobeNewswireANAHEIM, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it will be presenting at
- 5y agoBICXBioCorRx Files Patent Application with USPTO for Naltrexone ImplantGlobeNewswireANAHEIM, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent appli